Schrodinger (SDGR) said Q2 annual contract value (ACV) growth accelerated as demand broadened across large pharma, biotech and materials-science customers. The company also launched early access for Bunsen, its agentic AI co-scientist. Overall, the combination of faster ACV momentum and a new AI product feature should be supportive for near-term sentiment, but no margin or guidance numbers were provided.
Schrodinger (SDGR) said Q2 annual contract value (ACV) growth accelerated as demand broadened across large pharma, biotech and materials-science customers. The company also launched early access for Bunsen, its agentic AI co-scientist. Overall, the combination of faster ACV momentum and a new AI product feature should be supportive for near-term sentiment, but no margin or guidance numbers were provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
